I-Orforglipron yinoveli yohlobo lwe-2 yeswekile kunye neyeza lokunciphisa umzimba phantsi kophuhliso kwaye kulindeleke ukuba ibe yinto yomlomo yomlomo kumachiza atofwayo. Ivela kwi-glucagon-like peptide-1 (GLP-1) intsapho ye-agonist ye-receptor kwaye ifana ne-Wegovy esetyenziswa ngokuqhelekileyo (i-Semaglutide) kunye ne-Mounjaro (i-Tirzepatide). Inemisebenzi yokulawula iswekile yegazi, ukucinezela ukutya kunye nokuphucula ukuhlutha, ngaloo ndlela inceda ukulawula ubunzima kunye namaqondo eswekile yegazi.
Ngokungafaniyo namachiza amaninzi e-GLP-1, inzuzo ekhethekileyo ye-Orforglipron ilele kwifomu yayo yethebhulethi yomlomo yemihla ngemihla kunolawulo lweveki okanye lwemihla ngemihla. Le ndlela yolawulo iphucule kakhulu ukuthotyelwa kwezigulane kunye nokulula kokusetyenziswa, okumela ukuqhubela phambili okubalulekileyo kwabo bangazithandiyo iinaliti okanye abanesimo sengqondo sokuxhathisa kwiinaliti.
Kuvavanyo lweklinikhi, i-Orforglipron ibonise iziphumo ezibalaseleyo zokwehla kobunzima. Idatha ibonisa ukuba abathathi-nxaxheba abathatha i-Orforglipron imihla ngemihla kwiiveki ze-26 ezilandelelanayo bafumana ukulahleka kwesisindo esiphakathi kwe-8% ukuya kwi-12%, ebonisa ukusebenza kwayo okubalulekileyo ekulawuleni ubunzima. Ezi ziphumo zenze i-Orforglipron yaba lithemba elitsha lonyango lwexesha elizayo lohlobo lwe-2 yeswekile kunye nokutyeba, kwaye ikwabonisa umkhwa obalulekileyo kwicandelo lamachiza e-GLP-1, elisuka kwi-injection ukuya kwiifom zedosi yomlomo.
Ixesha lokuposa: Jul-07-2025